Abstract
A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Autoimmune Diseases / immunology
-
Autoimmune Diseases / therapy*
-
Disease Progression
-
Double-Blind Method
-
Female
-
HLA-DR Antigens / analysis
-
HLA-DRB1 Chains
-
Humans
-
Immunotherapy, Active*
-
Interleukin-10 / physiology
-
Male
-
Middle Aged
-
Multiple Sclerosis / immunology
-
Multiple Sclerosis / therapy*
-
Myelin Basic Protein / immunology
-
Peptide Fragments / immunology*
-
Pilot Projects
-
Receptors, Antigen, T-Cell, alpha-beta / immunology*
-
T-Lymphocyte Subsets / immunology
-
Th2 Cells / immunology
-
Vaccines / administration & dosage
-
Vaccines / immunology*
Substances
-
HLA-DR Antigens
-
HLA-DRB1 Chains
-
Myelin Basic Protein
-
Peptide Fragments
-
Receptors, Antigen, T-Cell, alpha-beta
-
Vaccines
-
Interleukin-10